% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Weisser:128518,
      author       = {M. Weisser and R.-F. Yeh and G. Duchateau-Nguyen and G.
                      Palermo and T. Q. Nguyen and X. Shi and S. Y. Stinson and N.
                      Yu and A. Dufour and T. Robak and G. N. Salogub and A.
                      Dmoszynska and P. Solal-Celigny and K. Warzocha and J.
                      Loscertales and J. Catalano and L. Larratt and V. A. Rossiev
                      and I. Bence-Bruckler and C. H. Geisler and M. Montillo and
                      K. Fischer and A.-M. Fink and M. Hallek and J. Bloehdorn and
                      R. Busch and A. Benner$^*$ and H. Döhner and N. Valente and
                      M. K. Wenger and S. Stilgenbauer and D. Dornan},
      title        = {{PTK}2 expression and immunochemotherapy outcome in chronic
                      lymphocytic leukemia.},
      journal      = {Blood},
      volume       = {124},
      number       = {3},
      issn         = {1528-0020},
      address      = {Stanford, Calif.},
      publisher    = {HighWire Press},
      reportid     = {DKFZ-2017-04534},
      pages        = {420 - 425},
      year         = {2014},
      abstract     = {Addition of rituximab (R) to fludarabine and
                      cyclophosphamide (FC) has significantly improved patient
                      outcomes in chronic lymphocytic leukemia (CLL). Whether
                      baseline gene expression can identify patients who will
                      benefit from immunochemotherapy over chemotherapy alone has
                      not been determined. We assessed genome-wide expression of
                      300 pretreatment specimens from a subset of 552 patients in
                      REACH, a study of FC or R-FC in relapsed CLL. An independent
                      test set was derived from 282 pretreatment specimens from
                      CLL8, a study of FC or R-FC in treatment-naïve patients.
                      Genes specific for benefit from R-FC were determined by
                      assessing treatment-gene interactions in Cox proportional
                      hazards models. REACH patients with higher pretreatment
                      protein tyrosine kinase 2 (PTK2) messenger RNA levels
                      derived greater benefit from R-FC, with significant
                      improvements in progression-free survival, independent of
                      known prognostic factors in a multivariate model.
                      Examination of PTK2 gene expression in CLL8 patients yielded
                      similar results. Furthermore, PTK2 inhibition blunted
                      R-dependent cell death in vitro. This retrospective analysis
                      from 2 independent trials revealed that increased PTK2
                      expression is associated with improved outcomes for CLL
                      patients treated with R-FC vs FC. PTK2 expression may be a
                      useful biomarker for patient selection in future trials.
                      These trials were registered at www.clinicaltrials.gov as
                      #NCT00090051 (REACH) and #NCT00281918 (CLL8).},
      keywords     = {Antibodies, Monoclonal, Murine-Derived (NLM Chemicals) /
                      RNA, Messenger (NLM Chemicals) / RNA, Neoplasm (NLM
                      Chemicals) / Rituximab (NLM Chemicals) / Cyclophosphamide
                      (NLM Chemicals) / Focal Adhesion Kinase 1 (NLM Chemicals) /
                      PTK2 protein, human (NLM Chemicals) / Vidarabine (NLM
                      Chemicals) / fludarabine (NLM Chemicals)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24916506},
      doi          = {10.1182/blood-2013-12-538975},
      url          = {https://inrepo02.dkfz.de/record/128518},
}